The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
The Merck KGaA/Pfizer drug is said to have cured 52% of women with a rare gynaecological cancer, one of whom subsequently gave birth.
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.
The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.